Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Young L, Dong O, Wiltshire T, Kypzyk K, Guenzel N. MC4R polymorphism associated with antipsychotic-associated weight gain. Poster presented at the 11th Congress of the International Society of Nutrigenetics and Nutrigenomics Annual Meeting; September 17, 2017. Los Angeles, CA. [abstract] J Nutrigenet Nutrigenomics. 2017; 10:121. doi: 10.1159/000480052
Dong OM, Suzuki O, Howard R, Jamieson K, Pointer M, Kohlmeier T, Wiltshire T. Using targeted next-generation sequencing as a cost-efficient method to characterize the genetics of salt sensitivity. Poster presented at the 11th Congress of the International Society of Nutrigenetics and Nutrigenomics Annual Meeting; September 18, 2017. Los Angeles, CA. [abstract] J Nutrigenet Nutrigenomics. 2017; 10:100. doi: 10.1159/000480052
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
McKenna SP, Doward LC. How should we measure quality of life in ankylosing spondylitis? Rheumatol Pract. 2008;6(2):12-4.